292 related articles for article (PubMed ID: 26363012)
1. Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198.
Molenaar RJ; Botman D; Smits MA; Hira VV; van Lith SA; Stap J; Henneman P; Khurshed M; Lenting K; Mul AN; Dimitrakopoulou D; van Drunen CM; Hoebe RA; Radivoyevitch T; Wilmink JW; Maciejewski JP; Vandertop WP; Leenders WP; Bleeker FE; van Noorden CJ
Cancer Res; 2015 Nov; 75(22):4790-802. PubMed ID: 26363012
[TBL] [Abstract][Full Text] [Related]
2. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC
PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816
[TBL] [Abstract][Full Text] [Related]
3. Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death.
Mohrenz IV; Antonietti P; Pusch S; Capper D; Balss J; Voigt S; Weissert S; Mukrowsky A; Frank J; Senft C; Seifert V; von Deimling A; Kögel D
Apoptosis; 2013 Nov; 18(11):1416-1425. PubMed ID: 23801081
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors.
Chitneni SK; Reitman ZJ; Spicehandler R; Gooden DM; Yan H; Zalutsky MR
Bioorg Med Chem Lett; 2018 Feb; 28(4):694-699. PubMed ID: 29366652
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of a novel mutant isocitrate dehydrogenase 1 inhibitor for glioma treatment.
Zhang N; Zheng B; Yao X; Huang X; Du J; Shen Y; Huang Z; Chen J; Lin Q; Lan W; Lin W; Ma W
Biochem Biophys Res Commun; 2021 Apr; 551():38-45. PubMed ID: 33714758
[TBL] [Abstract][Full Text] [Related]
6. A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas.
Fujii Y; Ogasawara S; Oki H; Liu X; Kaneko MK; Takano S; Kato Y
Biochem Biophys Res Commun; 2015 Oct; 466(4):733-9. PubMed ID: 26381180
[TBL] [Abstract][Full Text] [Related]
7. NADP+ -dependent IDH1 R132 mutation and its relevance for glioma patient survival.
Baldewpersad Tewarie NM; Burgers IA; Dawood Y; den Boon HC; den Brok MG; Klunder JH; Koopmans KB; Rademaker E; van den Broek HB; van den Bersselaar SM; Witjes JJ; Van Noorden CJ; Atai NA
Med Hypotheses; 2013 Jun; 80(6):728-31. PubMed ID: 23541771
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer.
Wu F; Cheng G; Yao Y; Kogiso M; Jiang H; Li XN; Song Y
Med Chem; 2018; 14(7):715-724. PubMed ID: 29792149
[TBL] [Abstract][Full Text] [Related]
9. IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced.
Zhu H; Zhang Y; Chen J; Qiu J; Huang K; Wu M; Xia C
PLoS One; 2017; 12(1):e0169038. PubMed ID: 28052098
[TBL] [Abstract][Full Text] [Related]
10. Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer.
Brooks E; Wu X; Hanel A; Nguyen S; Wang J; Zhang JH; Harrison A; Zhang W
J Biomol Screen; 2014 Sep; 19(8):1193-200. PubMed ID: 24980596
[TBL] [Abstract][Full Text] [Related]
11. A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation.
Duncan CG; Barwick BG; Jin G; Rago C; Kapoor-Vazirani P; Powell DR; Chi JT; Bigner DD; Vertino PM; Yan H
Genome Res; 2012 Dec; 22(12):2339-55. PubMed ID: 22899282
[TBL] [Abstract][Full Text] [Related]
12. Functions of idh1 and its mutation in the regulation of developmental hematopoiesis in zebrafish.
Shi X; He BL; Ma AC; Guo Y; Chi Y; Man CH; Zhang W; Zhang Y; Wen Z; Cheng T; Leung AY
Blood; 2015 May; 125(19):2974-84. PubMed ID: 25778530
[TBL] [Abstract][Full Text] [Related]
13. Increased
Koyasu S; Shimizu Y; Morinibu A; Saga T; Nakamoto Y; Togashi K; Harada H
J Neurooncol; 2019 Dec; 145(3):441-447. PubMed ID: 31667733
[TBL] [Abstract][Full Text] [Related]
14. Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype.
Cuyàs E; Fernández-Arroyo S; Corominas-Faja B; Rodríguez-Gallego E; Bosch-Barrera J; Martin-Castillo B; De Llorens R; Joven J; Menendez JA
Oncotarget; 2015 May; 6(14):12279-96. PubMed ID: 25980580
[TBL] [Abstract][Full Text] [Related]
15. CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP.
Moure CJ; Diplas BH; Chen LH; Yang R; Pirozzi CJ; Wang Z; Spasojevic I; Waitkus MS; He Y; Yan H
Mol Cancer Res; 2019 Oct; 17(10):2042-2050. PubMed ID: 31292202
[TBL] [Abstract][Full Text] [Related]
16. Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.
Davis MI; Gross S; Shen M; Straley KS; Pragani R; Lea WA; Popovici-Muller J; DeLaBarre B; Artin E; Thorne N; Auld DS; Li Z; Dang L; Boxer MB; Simeonov A
J Biol Chem; 2014 May; 289(20):13717-25. PubMed ID: 24668804
[TBL] [Abstract][Full Text] [Related]
17. The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma.
Bleeker FE; Atai NA; Lamba S; Jonker A; Rijkeboer D; Bosch KS; Tigchelaar W; Troost D; Vandertop WP; Bardelli A; Van Noorden CJ
Acta Neuropathol; 2010 Apr; 119(4):487-94. PubMed ID: 20127344
[TBL] [Abstract][Full Text] [Related]
18. Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL.
Karpel-Massler G; Ishida CT; Bianchetti E; Zhang Y; Shu C; Tsujiuchi T; Banu MA; Garcia F; Roth KA; Bruce JN; Canoll P; Siegelin MD
Nat Commun; 2017 Oct; 8(1):1067. PubMed ID: 29057925
[TBL] [Abstract][Full Text] [Related]
19. IDH1
Kim GH; Choi SY; Oh TI; Kan SY; Kang H; Lee S; Oh T; Ko HM; Lim JH
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151327
[TBL] [Abstract][Full Text] [Related]
20. Extracellular glutamate and IDH1
Tiburcio PDB; Gillespie DL; Jensen RL; Huang LE
J Neurooncol; 2020 Feb; 146(3):427-437. PubMed ID: 32020473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
